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Introduction
Sepsis is a common cause of  death in developed countries (1). Cardiac involvement frequently compli-
cates sepsis. One hospital-based study found that 43% of  patients with bacteremia had positive serum 
troponin, indicating myocardial damage (2). Clinical studies have shown that if  sepsis causes cardiac 
systolic dysfunction (also called sepsis-induced cardiomyopathy) the mortality rate increases up to 
80%, compared with a 20% mortality rate for sepsis with normal systolic function (3, 4). Sepsis can 
also cause abnormal cardiac electrophysiology, as indicated by the fact that patients with sepsis often 
have abnormal electrocardiograms and/or arrhythmias (5, 6). Atrial fibrillation is 6 times more com-
Cardiomyopathy frequently complicates sepsis and is associated with increased mortality. Increased 
cardiac oxidative stress and mitochondrial dysfunction have been observed during sepsis, but the 
mechanisms responsible for these abnormalities have not been determined. We hypothesized that 
NADPH oxidase 2 (NOX2) activation could be responsible for sepsis-induced oxidative stress and 
cardiomyopathy. Treatment of isolated adult mouse cardiomyocytes with low concentrations of 
the endotoxin lipopolysaccharide (LPS) increased total cellular reactive oxygen species (ROS) and 
mitochondrial superoxide. Elevated mitochondrial superoxide was accompanied by depolarization 
of the mitochondrial inner membrane potential, an indication of mitochondrial dysfunction, and 
mitochondrial calcium overload. NOX2 inhibition decreased LPS-induced superoxide and prevented 
mitochondrial dysfunction. Further, cardiomyocytes from mice with genetic ablation of NOX2 did 
not have LPS-induced superoxide or mitochondrial dysfunction. LPS decreased contractility and 
calcium transient amplitude in isolated cardiomyocytes, and these abnormalities were prevented by 
inhibition of NOX2. LPS decreased systolic function in mice, measured by echocardiography. NOX2 
inhibition was cardioprotective in 2 mouse models of sepsis, preserving systolic function after LPS 
injection or cecal ligation and puncture (CLP). These data show that inhibition of NOX2 decreases 
oxidative stress, preserves intracellular calcium handling and mitochondrial function, and alleviates 
sepsis-induced systolic dysfunction in vivo. Thus, NOX2 is a potential target for pharmacotherapy 
of sepsis-induced cardiomyopathy.
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mon in patients admitted to the ICU with sepsis compared with other diagnoses (7). Currently, there is 
no therapy for sepsis-induced cardiomyopathy.
Introduction of  live bacteria or injection of  the bacterial endotoxin lipopolysaccharide (LPS) have been 
used for animal models of  sepsis. Studies of  human blood metabolites show that LPS injection correlates with 
the abnormalities seen in sepsis (8). A variety of  mechanisms have been proposed to explain cardiomyopathy 
during sepsis, including increased reactive oxygen species (ROS) as an important part of  the pathophysiology 
(9, 10). Mitochondrial dysfunction has been a consistent finding in sepsis models, with decreased mitochon-
drial oxidative phosphorylation and decreased transcription of  mitochondrial genes (11–13). Abnormalities 
of  intracellular calcium handling have also been observed in cardiomyocytes from animal models of  sepsis 
(14–17). Multiple stress-related kinases are activated in the heart during sepsis, including protein kinase C 
(PKC) and c-Jun N-terminal kinase (JNK) (18, 19). However, there is no unified explanation of  these multiple 
cardiac abnormalities. Specifically, the mechanisms responsible for increased oxidative stress and mitochon-
drial dysfunction in the heart during sepsis remain obscure, and it is not understood how these abnormalities 
may be related to abnormal intracellular calcium handling. We hypothesized that NADPH oxidase 2 (NOX2) 
activation is the primary mechanism causing systolic dysfunction during sepsis.
Results
LPS increases oxidative stress in cardiomyocytes and causes mitochondrial dysfunction. We quantified oxida-
tive stress in ventricular cardiomyocytes, and found that low concentrations of  LPS increased total 
cellular ROS after 1-hour exposure (as indicated by 2′,7′-dichlorofluorescin diacetate [DCF] fluores-
cence). There was a stepwise increase in ROS with escalating doses of  LPS (Figure 1A). LPS also 
increased mitochondrial superoxide significantly in cardiomyocytes, as indicated by MitoSOX Red 
fluorescence, which is a mitochondrial superoxide indicator (Figure 1B). Mitochondria can produce 
several species of  ROS, but superoxide is the most proximal (20). To better characterize the mitochon-
drial abnormalities induced by LPS, we quantified the mitochondrial inner membrane potential using 
tetramethylrhodamine methyl ester (TMRM) (21). Normally, the mitochondrial inner membrane has a 
voltage gradient, with the interior negative in relation to the cytosol. LPS causes partial depolarization 
of  the mitochondrial inner membrane potential, an indication of  mitochondrial dysfunction (Figure 
1C). Partial depolarization of  the inner membrane potential can be caused by excessive mitochondrial 
calcium uptake (22). To evaluate calcium overload as a cause of  mitochondrial dysfunction, we quan-
tified mitochondrial calcium levels during LPS treatment and found that LPS caused mitochondrial 
calcium overload, in a dose-responsive manner (Figure 1D).
To determine the effects of  LPS on mitochondrial oxidative phosphorylation, we used the H9c2 
cardiomyoblast cell line. Cells were exposed to LPS and then mitochondrial oxygen consumption was 
quantified with a Seahorse system. The results show that LPS causes a significant decrease in maxi-
mal mitochondrial oxidative phosphorylation (induced by pharmacologic uncoupling) after a 2-hour 
exposure (Figure 1E). There was no significant difference after 1-hour exposure, indicating that mito-
chondria are able to function in the early stages of  LPS exposure despite increased oxidative stress.
LPS increases calcium sparks, and RyR inhibition reduces mitochondrial dysfunction and oxidative stress. Previ-
ous work has shown that sepsis-induced cardiomyopathy is characterized by increased sarcoplasmic reticu-
lum calcium leak (23). To determine if  LPS is sufficient to increase sarcoplasmic reticulum calcium leak 
independently of  immune response, we measured sparks (spontaneous calcium release events) in isolated 
cardiomyocytes. This showed that 1 hour of  LPS exposure is sufficient to cause a significant increase in 
sparks (Figure 2, A–C). To verify that ryanodine receptor–mediated (RyR-mediated) calcium leak causes 
mitochondrial calcium overload, we used dantrolene, which inhibits opening of  RyR channels. Dantrolene 
prevented the increase in mitochondrial calcium caused by LPS. Dantrolene also reduced oxidative stress 
and blunted the partial depolarization of  the inner membrane (Figure 2, D–G).
In cardiac ischemia/reperfusion, it is known that mitochondrial calcium overload causes opening 
of  the mitochondrial permeability transition pore (mPTP), contributing to oxidative stress and cardiac 
dysfunction (24). To determine if  mPTP opening could be involved in sepsis, we inhibited the opening 
of  the mPTP with cyclosporin A. Cyclosporin A reduces mitochondrial superoxide after LPS exposure 
and offers some protection from mitochondrial depolarization (Figure 2, D–G). We infer that LPS-
induced sarcoplasmic reticulum calcium leak leads to mitochondrial calcium overload and opening of  
the mPTP, which contributes to mitochondrial depolarization and superoxide production.
Downloaded from http://insight.jci.org on September 7, 2017.   https://doi.org/10.1172/jci.insight.94248
3insight.jci.org   https://doi.org/10.1172/jci.insight.94248
R E S E A R C H  A R T I C L E
NOX2 activation is required for LPS-induced ROS. Next, we investigated the mechanism by which LPS causes 
increased oxidative stress and sarcoplasmic reticulum calcium leak. Mitochondria are a major source of ROS 
in cardiomyocytes, but NOX isoforms have also been implicated in the pathophysiology of sepsis (25). Fur-
thermore, NOX2 activation is known to increase sarcoplasmic reticulum calcium release (26). We used the 
lucigenin assay to quantify NOX2 production of superoxide, which confirmed that LPS rapidly activates NOX2 
in cardiomyocytes (Figure 3A). The NOX inhibitor apocynin prevented NOX activation by LPS (Figure 3A). 
We also used a NOX2 inhibitor peptide, gp91ds-tat, to ensure specificity, confirming that NOX2 is the source 
of LPS-stimulated superoxide (Figure 3A). It is known that NOX2 can be activated by PKC isoforms in cardio-
myocytes (27). To determine if  PKC activation is required for the pathophysiology caused by LPS, we used the 
broad-spectrum PKC inhibitor Go6983, which prevented NOX activation by LPS (Figure 3A).
We used the NOX2 inhibitor peptide to evaluate the contribution of  NOX2 to LPS-induced oxidative 
stress. The inhibitor peptide reduced, but did not normalize, the increase in oxidative stress caused by LPS 
(Figure 3, B and C). The inhibitor peptide prevented the decrease in inner membrane potential and prevent-
ed the increase in mitochondrial calcium (Figure 3, D and E). This shows that NOX2 activation contributes 
to LPS-induced oxidative stress and mitochondrial dysfunction. The PKC inhibitor Go6983 reduced total 
and mitochondrial ROS caused by LPS (Figure 3, B and C), consistent with PKC being upstream of  NOX 
activation. The PKC inhibitor also prevented the decrease in mitochondrial membrane potential and mito-
chondrial calcium overload (Figure 3, D and E).
To confirm the pharmacologic data, we used NOX2-KO mice, which did not have increased oxida-
tive stress after exposure to LPS (Figure 3,  F and G). In addition, NOX2-KO cardiomyocytes did not 
have mitochondrial depolarization or mitochondrial calcium overload after LPS treatment (Figure 3, H 
and I). This indicates that NOX2 activation is necessary for LPS-induced oxidative stress and mitochon-
drial dysfunction in cardiomyocytes.
Figure 1. LPS increases oxidative stress in cardiomyocytes and causes mitochondrial dysfunction. (A) Representa-
tive experiment done with WT adult mouse ventricular myocytes (AMVMs) in triplicate wells, 2,000 cells/well; height 
is DCF fluorescence minus background, arbitrary units, in live cells, mean + SEM. LPS increases ROS significantly. LPS = 
lipopolysaccharide 5 or 20 ng/ml as noted, 1-hour exposure. (B) Cardiomyocytes from the same experiment using Mito-
SOX Red readout, arbitrary units, to indicate mitochondrial superoxide. (C) Cardiomyocytes from the same experiment 
using TMRM readout to indicate mitochondrial inner membrane depolarization. (D) Cardiomyocytes from the same 
experiment using Rhod 2-AM readout, arbitrary units, to indicate mitochondrial calcium load. For panels A–D, means 
are significantly different by ANOVA; *significantly different from control by post-hoc test. (E) Maximum oxygen 
consumption rate (OCR) is decreased in H9c2 cells by LPS. Measurements from 3 time points were obtained under each 
condition, using triplicate wells. P = 0.014 for comparison of control with 2-hour LPS at the FCCP step (to stimulate 
maximum oxygen consumption). b, baseline; o, oligomycin; F, FCCP; AA, antimycin-A and rotenone.
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LPS rapidly reduces contractility and causes abnormal calcium transients in cardiomyocytes, which is pre-
vented by NOX2 inhibition. Prior work has shown that cardiomyocytes from mice injected with LPS have 
abnormal calcium transients, with lower amplitude and longer decay phase (return to baseline) (23). 
To determine if  LPS exposure itself  is sufficient to cause decreased contractility and abnormal calcium 
transients, rather than activation of  the immune system, we exposed isolated WT cardiomyocytes 
to LPS for 1 hour and then measured contractility and calcium transients. LPS caused a significant 
decrease in contractility in ventricular cardiomyocytes after a 1-hour exposure (Figure 4, A and C). 
Calcium transients from cardiomyocytes exposed to LPS had significantly decreased amplitude, and a 
longer decay phase as quantified by the time constant tau (Figure 4, B and D). We evaluated the effect 
of  inhibition of  NOX2 on isolated cardiomyocyte contractility and calcium transients. Apocynin pre-
vented the decrease in contractility and calcium transient amplitude induced by LPS exposure, indicat-
ing that NOX2 activation is necessary for abnormal calcium handling after LPS exposure (Figure 4, 
C and D). The same effects were evident at faster pacing rates (Supplemental Figure 1; supplemental 
material available online with this article; https://doi.org/10.1172/jci.insight.94248DS1).
Decreased calcium transient amplitude is consistent with either decreased sarcoplasmic reticulum cal-
cium stores or decreased fractional release. We evaluated sarcoplasmic reticulum calcium with the caffeine 
method. These results showed no significant change in sarcoplasmic reticulum calcium load 1 hour after 
LPS exposure, suggesting that decreased fractional release is responsible (Supplemental Figure 2). In sum-
mary, these results show that LPS is sufficient to decrease contractility and impair calcium handling in 
isolated cardiomyocytes in a NOX-dependent manner.
NOX2 inhibition is cardioprotective in a mouse model of  sepsis. To assess the significance of  NOX2 activation 
in septic cardiac dysfunction in vivo, we used a mouse model of  LPS-induced endotoxemia (11, 28). Wild-
type (WT) mice were injected with LPS, which is known to decrease cardiac contractility, and then we 
assessed cardiac function by echocardiography. Inhibition of  NOX activity with apocynin has a protective 
Figure 2. LPS increases calcium sparks, and RyR inhibition reduces LPS-induced ROS and mitochondrial dysfunction. 
(A) Representative image of calcium sparks in WT isolated adult mouse ventricular myocytes. (B) Image of calcium 
sparks in WT cardiomyocytes exposed to LPS for 1 hour. (C) Quantification of sparks in WT cardiomyocytes exposed to 
LPS for indicated time. n = 4 independent cardiomyocyte isolations. *Significantly different from control by unpaired 
t test. (D) Mitochondrial calcium in WT cardiomyocytes, Rhod 2-AM signal minus background, mean ± SEM, n= 3 inde-
pendent cardiomyocyte isolations. (E) Cellular ROS in WT cardiomyocytes, DCF fluorescence, mean ± SEM, n= 3 inde-
pendent cardiomyocyte isolations. (F) Mitochondrial ROS in WT cardiomyocytes, MitoSOX Red fluorescence, mean ± 
SEM, n = 3 independent cardiomyocyte isolations. (G) Mitochondrial inner membrane potential in WT cardiomyocytes, 
TMRM fluorescence, mean ± SEM, n = 3 independent cardiomyocyte isolations. For panels D–G, means are significantly 
different by ANOVA; *significantly different from control by post-hoc test. LPS = 20 ng/ml, 1-hour exposure. Dan, 1 μM 
dantrolene; CA, 20 μM cyclosporin A.
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effect on systolic function after LPS injection (Figure 5, A–C and Supplemental Table 1). Apocynin also 
prevented the increase in ventricular brain natriuretic peptide (BNP) expression, a marker of  heart failure 
(Figure 5D). Plasma levels of  IL-6 and TNF-α were not improved by apocynin, indicating that the benefit 
of  NOX2 inhibition is not mediated by reduction of  systemic inflammation (Figure 5, E and F).
In addition, NOX inhibition prevented activation of  cardiac JNK (Figure 5G). We have previously 
shown that the JNK pathway is activated in the heart during sepsis and is responsible for downregulation of  
genes required for normal mitochondrial respiration (13, 29). Consistent with this prior work, NOX inhibi-
tion prevented abnormal transcriptional regulation induced by LPS. LPS reduced cardiac mRNA levels of  
several genes that are critical for metabolism and mitochondrial function: Pparα, Pgc1α, and Cpt1β. Apocy-
nin prevented downregulation of  these genes (Figure 5H). Not all mitochondrial genes were downregulated 
by LPS. We found that LPS increased mRNA expression of  uncoupling protein 2 (Ucp2) and Ucp3 in the 
heart, and these levels were normalized by apocynin (Supplemental Figure 3).
Staining of  ventricular tissue with dihydroethidium demonstrated that LPS causes a significant 
increase in oxidative stress, and this was prevented by apocynin (Figure 6). Histology also showed that 
LPS increased cardiac NADPH levels, and this was not prevented by apocynin. Since NOX2 activation 
would tend to consume NADPH and increase levels of  NADP+, there must be compensatory mecha-
nisms to increase NADPH after exposure to LPS. For example, NADPH is used in many anabolic 
reactions, so a decrease in anabolic metabolism could increase tissue levels. Collectively, these data 
suggest that NOX2 activation is the major mechanism causing oxidative stress and systolic dysfunction 
in the early stages of  sepsis.
PKC and NOX2 inhibition are cardioprotective in a mouse model of  sepsis. Since our data show that PKC 
activation could be upstream of  NOX2 activation in isolated cardiomyocytes (Figure 3), we evaluated PKC 
isoforms in membrane preparation lysates from ventricular tissue of  mice injected with LPS or vehicle 
control. PKCα showed a nonsignificant trend towards activation, and PKCβ and PKCδ were significantly 
activated in the heart after LPS exposure (Figure 7, A and B). Interestingly, PKCβ has been identified as an 
activator of  NOX during cardiac lipotoxicity (30). There was also a corresponding decrease in membrane-
Figure 3. NOX2 activation is required for LPS-induced oxidative 
stress. (A) One-hour exposure to LPS increases NOX activity and 
NOX or PKC inhibition prevents the increase in NOX activity. Height is 
lucigenin luminescence, in arbitrary units, from WT mouse cardio-
myocytes lysates, n = 3 independent cardiomyocyte isolations. (B) 
PKC and NOX2 inhibitors prevent LPS-induced ROS in isolated WT 
cardiomyocytes. DCF fluorescence minus background, in live cells, 
mean ± SEM. n = 3 independent cardiomyocyte isolations. (C) PKC and 
NOX2 inhibitors prevent LPS-induced mitochondrial ROS in isolated 
WT cardiomyocytes. MitoSOX Red fluorescence minus background, in 
live cells, mean ± SEM, n = 3 independent cardiomyocyte isolations. 
(D) PKC and NOX2 inhibitors prevent the loss of mitochondrial inner 
membrane potential in isolated WT cardiomyocytes. TMRM readout in 
live cells, mean ± SEM, n = 3 independent cardiomyocyte isolations. (E) 
PKC and NOX2 inhibitors prevent the increase in mitochondrial calcium 
in isolated WT cardiomyocytes. Rhod 2-AM readout in live cells, mean 
± SEM, n = 3 independent cardiomyocyte isolations. (F) LPS does not 
induce ROS in isolated NOX2-KO cardiomyocytes. DCF fluorescence 
minus background, in live cells, mean ± SEM, n = 3 independent car-
diomyocyte isolations. (G) LPS does not induce mitochondrial ROS in 
isolated NOX2-KO cardiomyocytes. MitoSOX Red fluorescence minus 
background, in live cells, mean ± SEM. n = 3 independent cardiomyo-
cyte isolations. (H) LPS does not decrease the mitochondrial inner 
membrane potential in isolated NOX2-KO cardiomyocytes. TMRM fluo-
rescence minus background, in live cells, mean ± SEM. n = 3 indepen-
dent cardiomyocyte isolations. (I) LPS does not increase mitochondrial 
calcium in isolated NOX2-KO cardiomyocytes. Rhod 2-AM fluorescence 
minus background, in live cells, mean ± SEM. n = 3 independent cardio-
myocyte isolations. For all panels, means are significantly different by 
ANOVA; *significantly different from control by post-hoc test. LPS = 
20 ng/ml, 1-hour exposure; apo = 200 μM apocynin; Go = 5 μm Go6983 
PKC inhibitor; gp91 = gp91ds-tat NOX2 inhibitor peptide.
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bound PKCε (Figure 7B). We evaluated the in vivo benefit of  PKC inhibition using the same animal model 
of  sepsis. The broad-spectrum PKC inhibitor Ro-31-8220 prevented cardiac systolic function after LPS 
injection, consistent with PKC activation upstream of  NOX2 activation (Figure 7, C and D).
Live bacteria model of  sepsis confirms that PKC and NOX2 inhibition are protective. To confirm the results 
of  the LPS injection model, we used an established model of  polymicrobial sepsis, cecal ligation and 
puncture (CLP) (31). Serial echocardiograms demonstrated a gradual reduction in ejection fraction after 
CLP (Supplemental Figure 4). We confirmed that NOX activity is increased in the heart after CLP, and 
apocynin blunts this increase in NOX activity (Figure 8A). We also confirmed that PKC isoforms were 
activated in the hearts of  mice after CLP (Supplemental Figure 4). Notably, PKCβ was activated in both 
the LPS injection and CLP mouse models. Both the PKC inhibitor and apocynin had a protective effect 
on cardiac systolic function in the CLP model (Figure 8, B and C). Consistent with the LPS injection 
data, neither treatment had a significant antiinflammatory effect in the CLP model based on cardiac tis-
sue inflammatory gene expression (Figure 8D). Metabolic gene expression in the heart was improved by 
the PKC inhibitor in the CLP model (Figure 8E).
To evaluate apocynin as a therapy after the onset of  sepsis, another group of  mice were treated with 
apocynin 9 hours after CLP surgery, since this is the time point that showed a consistent reduction in ejection 
fraction. At 12 hours after CLP we evaluated the cardiac function, and then sacrificed the mice. Apocynin 
given after the onset of  sepsis showed a trend toward improved ejection fraction (Supplemental Figure 5).
We also evaluated cardiac function 24 hours after CLP surgery. For this experiment we gave the first 
dose of  apocynin during CLP and the second dose at 12 hours after CLP; 24 hours after CLP we evaluated 
Figure 4. LPS rapidly reduces 
contractility and causes 
abnormal calcium tran-
sients in cardiomyocytes, 
which is prevented by NOX2 
inhibition. (A) Representa-
tive raw data of isolated WT 
cardiomyocyte contractility, 
sarcomere length in μm, in 
cardiomyocytes under control 
conditions or treated with 
LPS. (B) Representative 
calcium transients from WT 
cardiomyocytes under control 
conditions or treated with 
LPS. (C) Graph of isolated 
cardiomyocyte contractility 
paced at 1 Hz, as percentage 
sarcomere shortening from 
baseline sarcomere length, for 
WT cardiomyocytes treated 
with LPS and/or apocynin 
(apo), mean ± SEM. (D) Graph 
of maximum amplitude of 
calcium transients, expressed 
as percentage change from 
baseline for WT cardiomyo-
cytes treated with LPS and/
or apocynin (apo), mean ± 
SEM. For panels C and D, n = 
3 different cardiac isolations 
(5–10 cells averaged per group 
for each isolation); the means 
are different by ANOVA; 
*significantly different from 
control by post-hoc test.
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the cardiac function with echocardiography. Mice in the sham and CLP groups received vehicle (DMSO) 
at both time points as a control. We also took blood at 24 hours after CLP to measure white blood cell 
(WBC) count, another measure of  immune system activation. Apocynin preserved the ejection fraction at 
24 hours (Supplemental Figure 6, A and B). Both the CLP vehicle group and the CLP+apocynin group had 
a decrease in WBC compared with sham (Supplemental Figure 6C). However, apocynin did not improve 
mortality (Supplemental Figure 6D). Additional work did not show a difference in P-ERK (a marker of  
activation of  the ERK stress kinase) after CLP (Supplemental Figure 7).
Figure 5. NOX2 inhibition prevents cardiomyopathy in vivo but does not prevent inflammation. (A) Representative M-mode echocardiograms. (B) Graph 
of fractional shortening (FS), n = 4–5 mice. (C) Graph of left ventricular internal dimensions during systole (LVIDs), n = 4–5 mice. (D) Graph of ventricular 
BNP mRNA levels, n = 4–5 mice. (E and F) Plasma levels of IL-6 and TNF-α, n = 4–5 mice. (G) Graph of multiplex protein analysis for p-JNK adjusted relative 
to β-tubulin. n = 4–5 mice. (H) Graph of metabolic gene expression from ventricular tissue. n = 6–8 heart samples. All panels show data from C57BL/6 mice 
treated with saline (control), apocynin, LPS, or combination of LPS and apocynin. *P < 0.05, **P < 0.01 compared with control by ANOVA with post-hoc testing.
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Figure 6. Apocynin reduces superoxide in cardiac tissue (left ventricle). (A) Representative confocal images of superoxide detection by dihydroethid-
ium (DHE) and NADPH autofluorescence (blue color) in left ventricular tissue slices from control mice. DHE signal is indicated by the red to white range 
indicator. Scale bars: 50 μm, with high magnification (×2 zoom of merged images) inset indicated by dashed square. (B) Representative confocal image 
from apocynin-treated tissue for superoxide and NADPH. Same scale as A. (C) Representative confocal image from LPS-treated tissue for superoxide and 
NADPH. (D) LPS+apocynin–treated representative confocal image. (E) Quantification of NADPH signal from control, apocynin, LPS, and LPS+apocynin 
heart samples. (F) Quantification of superoxide signal from control, apocynin, LPS, and LPS+apocynin heart samples. n = 3–6 mice/group. *P < 0.05, **P < 
0.01, ***P < 0.001 by ANOVA with post-hoc testing.
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Discussion
Sepsis is a common disease with a high mortality rate. Cardiac complications of  sepsis are associated with a 
worse prognosis. Currently, there is no effective treatment for sepsis-induced cardiomyopathy. Studies using 
human tissue samples have shown that cardiomyocyte cell death is rare during sepsis and does not explain 
the decrease in systolic function (32). Despite years of  research, the cellular mechanisms of  systolic dysfunc-
tion during sepsis remain unclear (33). Multiple abnormalities have been reported, using cardiomyocytes and 
animal models, without the identification of  a central mechanism. We used both in vivo and cellular model 
systems at early time points to identify the factors that initiate contractile dysfunction. We found that LPS is 
sufficient to rapidly increase mitochondrial superoxide and decrease contractility in isolated cardiomyocytes, 
and NOX2 activation is required for these abnormalities. Further, we show that in vivo inhibition of  NOX2 
protects mice from sepsis-induced systolic dysfunction using both the LPS-injection model and the CLP 
model of  polymicrobial sepsis. We propose that sepsis activates cardiac NOX2, which increases sarcoplas-
mic reticulum calcium leak, impairing cardiomyocyte contractility and leading to mitochondrial dysfunction 
(Figure 8). NOX2 inhibition also reduces JNK activation and downregulation of  metabolic genes (Figure 5).
Previous work has shown that exposing ventricular myocytes to higher doses of  LPS for 24 hours is suf-
ficient to reduce contractility (34). We used lower doses of  LPS and early time points to identify the initiating 
factors that lead to sepsis-induced cardiomyopathy. We show that inhibition of  NOX2 is protective in both 
isolated cardiomyocyte experiments and in animal models of  sepsis. This is the first time to our knowledge 
that pharmacologic NOX2 inhibition has been shown to prevent sepsis-induced contractile dysfunction in 
vivo. A prior report showing that NOX2-KO hearts were protected from the harmful effects of  LPS empha-
sized the role of  inflammation (35). Our data demonstrate a potentially novel mechanism that links NOX2 
activation with abnormal calcium handling and mitochondrial dysfunction. Importantly, NOX2 inhibition 
alleviated oxidative stress and preserved cardiac function without resolution of  the inflammatory component 
of  the disease based on serum cytokines, although apocynin may have an effect on WBC function. Thus, our 
study identifies a potentially novel role for NOX2 in the pathophysiology of  the disease, acting through mito-
chondria and cardiac metabolism in a way that is largely independent of  systemic inflammation.
NOX2 is known to transiently increase sarcoplasmic reticulum calcium release in cardiomyocytes in 
response to stretch (26). While this stretch response may be the physiologic function of  cardiac NOX2, 
long-term activation of  NOX2 may be maladaptive since it promotes arrhythmia (36) and heart failure 
(37). Previous work has demonstrated that sepsis increases sarcoplasmic reticulum calcium leak (sparks) in 
cardiomyocytes (23). Our experiments demonstrate that LPS is sufficient to increase calcium sparks. It is 
also possible that non–spark-mediated sarcoplasmic reticulum calcium leak contributes to the pathophysi-
ology. We also demonstrate smaller calcium transients after LPS exposure, which can be a direct cause of  
decreased cardiac contractility, since calcium release is essential for sarcomere contraction. Smaller-ampli-
tude calcium transients are characteristic of  systolic heart failure of  diverse etiologies (38). 
We propose that sepsis causes mitochondrial dysfunction through increased sarcoplasmic reticulum 
calcium leak, which promotes mitochondrial calcium overload and partial depolarization of  mitochon-
dria. Mitochondrial dysfunction may contribute to decreased cardiac contractility. The beneficial effect of  
cyclosporin A in our experiments confirms that mPTP opening contributes to mitochondrial dysfunction 
during sepsis (39). Opening of  the mPTP can be triggered by calcium overload (24). Increased calcium leak 
could also have harmful effects on cardiac transcription at later time points by activating NFAT and other 
calcium-sensitive transcriptional pathways, which have been associated with cardiac dysfunction (40).
Our data suggest that PKC-isoform activation is upstream of  NOX activation in the heart. PKCβ is a 
consistent finding in the 2 models and this is probably the activator of  NOX2. Although we show that NOX 
inhibition is effective at preserving contractility in vitro and in vivo, it is also possible that activation of  
PKC isoforms by LPS has harmful effects that are not mediated by NOX2. For example, the gene expres-
sion data from the CLP model indicate that PKC inhibition is more effective at normalizing metabolic gene 
expression than apocynin, the NOX inhibitor.
Figure 7. LPS activates PKCβ and PKCδ, and PKC inhibition improves cardiac function in vivo. (A) Western blots of PKC isoforms, membrane and cyto-
solic fraction, from ventricular tissue of mice treated with LPS or vehicle control. (B) Densitometric analysis of PKC Western blots, in relative units. *P < 
0.05, **P < 0.01 by unpaired t test (control vs. LPS for each fraction). Open circles are control, squares are LPS treatment. (C) Fractional shortening (FS) by 
echocardiogram, and (D) left ventricular internal diameter during systole (LVIDs). *P < 0.05, **P < 0.01 by ANOVA with post-hoc testing. All data are from 
C57BL/6 mice treated with saline, LPS, and/or PKC inhibitor Ro-31-8220, n = 4.
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Although immune system activation may contribute to cardiac dysfunction in later stages of  sepsis (41, 
42), our experiments show that LPS has a rapid, direct toxic effect on cardiomyocytes. Furthermore, the 
NOX2 inhibitor apocynin prevents systolic dysfunction in vivo, but it does not cause a reduction in circulat-
ing proinflammatory cytokines or cardiac tissue inflammatory gene expression, demonstrating that cardiac 
contractility and systemic inflammation can be dissociated. This finding is consistent with our previous find-
ings showing that induction of  cardiac fatty acid oxidation and energy production improved cardiac function 
prior to alleviation of  inflammation (11, 13). These new findings, in combination with our prior work, suggest 
a crucial role for restoration of  mitochondrial function and cardiac energetics as a way to maintain cardiac 
function in sepsis, independently of  systemic inflammation, at least for the early stage of  the disease.
The fact that NOX activation during sepsis decreases expression of genes that are required for mitochon-
drial function is a potentially novel finding. We have previously shown that LPS-mediated JNK activation is 
responsible for the decrease in expression of Pppara and other genes required for fatty acid oxidation by mito-
chondria (13). NOX2 inhibition prevents activation of JNK, which improves the expression of these genes. We 
Figure 8. CLP model is also protected by inhibition of PKC or NOX; diagram of proposed pathway. (A) Graph of lucigenin (NOX activity) from ventricular 
tissue lysates. n = 4 mice per group. (B) Representative M-mode echocardiograms  from C57BL/6 mice treated with vehicle control, PKC inhibitor Ro-31-
8220, or apocynin, at the time of cecal ligation and puncture (CLP) surgery. (C) Graph of echo data before and after CLP surgery. (D) Graph of inflammatory 
gene expression from ventricular tissue, n = 4–5 mice per group. (E) Graph of metabolic gene expression from ventricular tissue, n = 4-5 mice per group. (F) 
Diagram of proposed pathway. *P < 0.05, **P < 0.01, ***P < 0.001 by ANOVA with post-hoc testing.
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also found that cardiac expression of Ucp2 and Ucp3 was upregulated in the mouse model of sepsis. UCPs 
are mitochondrial transporter proteins that create proton leaks across the inner mitochondrial membrane, thus 
uncoupling oxidative phosphorylation from ATP synthesis. Superoxide activates UCPs (43), and UCP activa-
tion may decrease mitochondrial superoxide production (44). Although this may be an adaptive response to 
increased oxidative stress, increased UCP activity and/or expression would tend to decrease cardiac efficiency 
by decreasing the mitochondrial inner membrane potential.
Although the NOX inhibitor apocynin did not improve mortality by itself  in the rodent CLP model, it is 
possible that with intravenous fluid resuscitation and broad-spectrum antibiotics, NOX inhibitors could have 
additional benefit during septic shock complicated by cardiomyopathy. In conclusion, our results indicate that 
NOX2 activation is a critical factor in the pathophysiology of  sepsis-induced cardiomyopathy, acting at least 
in part independently of  systemic inflammation. NOX2 activation increases cardiac superoxide production, 
causes mitochondrial dysfunction, and decreases contractility. We used a small-molecule inhibitor of  NOX2 
in 2 different models of  sepsis to demonstrate the potential for translational application of  these findings. 
Although NOX2 inhibition could potentially reduce bactericidal functions of  WBCs, it is possible that selec-
tive, partial inhibition of  NOX2 in combination with antibiotics would be beneficial during sepsis.
Methods
Animal care, sepsis models, and cardiomyocyte isolation. WT and B6.129S-Cybbtm1Din/J (NOX2-KO) mice 
were purchased from The Jackson Laboratory and were 8–12 weeks old at the time of  experiments. 
LPS injections were performed as previously described (11) and animals were sacrificed 6–9 hours 
after LPS injections. Briefly, 5 mg/kg of  LPS (Sigma-Aldrich), which is a sublethal dose, was admin-
istered by intraperitoneal injection. Control mice were treated with an equal volume of  saline. Mice 
received a single intraperitoneal injection of  6 mg/kg Ro-31-8220 (Sigma-Aldrich) for PKC inhibition 
or 50 mg/kg apocynin for NOX inhibition. Both pharmacologic agents were administered 30 minutes 
prior to LPS injection. For CLP surgery, a 1- to 2-cm midline laparotomy was created to expose the 
cecum with the adjoining intestine. The cecum was ligated 1 cm from the distal end of  the cecum. The 
cecum was punctured twice with a 19-gauge needle and gently squeezed so that a small amount of  
feces was extruded. Mice were resuscitated by injecting 1 ml of  0.9% saline solution subcutaneously. 
Mice were injected with inhibitor compounds at the time of  surgery and again 6 hours later. Echocar-
diograms were performed 12 hours after CLP. Two-dimensional echocardiography was performed on 
anesthetized mice (inhaled isoflurane) using a VisualSonics Vevo 2100 machine. Echocardiographic 
images were recorded in a digital format. A single observer blinded to the respective treatments of  
mice then analyzed images off-line.
Cardiomyocyte isolation and measurements of  ROS, mitochondrial calcium, and mitochondria depolarization. 
Cardiomyocytes were isolated from adult mouse hearts using established protocols (45). Briefly, the heart 
was removed and the aorta was cannulated. After calcium-free buffer was perfused for 2 minutes, col-
lagenase (0.3 mg/ml; Liberase, Roche) solution was perfused through the coronary arteries for 7 minutes 
with calcium at 12.5 μM. Left ventricular tissue was teased apart and pipetted to release individual cells. 
After LPS and/or drug treatment, isolated cardiomyocytes were divided into aliquots. To measure ROS, 
cardiomyocytes were loaded with the fluorescent dye 2′,7′-dichlorofluorescin diacetate (DCF) (25 μM, 
Sigma-Aldrich) or MitoSOX Red (5 μM, Life Technologies), a mitochondrial superoxide indicator, was 
used to analyze mitochondrial superoxide generation within cardiomyocyte mitochondria, and incu-
bated for 30 minutes in the dark. Excess DCF or MitoSOX Red was removed with 2 washes of  BSA 
solution. DCF fluorescence was recorded at excitation/emission wavelengths of  488/532 nm, whereas 
MitoSOX Red was recorded at 525/620 nm. To assess the changes in mitochondrial membrane poten-
tial, cardiomyocytes were stained with 1 nM TMRM ester (Thermo Fisher Scientific) for 30 minutes 
and recorded at 543 nm (excitation)/590 nm (emission). TMRM preferentially accumulates inside mito-
chondria due to its positive charge. As mitochondria are depolarized, they trap less TMRM; thus, the 
signal is proportional to the inner membrane potential (46). To determine the changes in mitochondrial 
calcium in living cells, cardiomyocytes were loaded with 10 μM Rhod 2-AM (Thermo Fisher Scientific) 
and incubated for 30 minutes followed by 1-hour washout and cytosolic quenching with manganese, to 
produce a specific mitochondrial calcium signal (47). Rhod 2-AM fluorescence was measured at 552 nm 
(excitation)/581 nm (emission). Cells were loaded onto a 96-well plate in triplicate at 2,000 cells/well, 
and fluorescence was measured with a Tecan Infinite 200 plate reader.
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Single-cell contractility and calcium transients. Only rod-shaped cardiomyocytes with clear striations that 
were not spontaneously contracting at baseline were selected for experiments. Myocytes were field stimu-
lated at 1 Hz in a chamber contained Tyrode’s solution with 1.8 mM CaCl2 at room temperature. Imaging 
and quantification were performed using Ionoptix software Ionwizard 6.2. Sarcomere length measurements 
were performed using a fast Fourier transform algorithm. For experiments to evaluate calcium transients, 
cardiomyocytes were loaded with 1 μM fura-2 AM (Molecular Probes) for 10 minutes at room temperature, 
followed by two 10-minute washes. Calcium transients were quantified as the ratio of  fura-2 emission.
Sparks and caffeine release experiments. Sparks were recorded with a Leica SP2 confocal microscope 
equipped with a 63× 1.4 NA objective. Cardiomyocytes were loaded with fluo-4-AM (5 μM, 10 minutes; 
Thermo Fisher Scientific), in modified Tyrode’s solution containing 1 mM calcium. Line scan images were 
recorded with Leica TCS software and quantified with the Sparkmaster plugin of  ImageJ (NIH). For caf-
feine release experiments, cardiomyocytes were loaded with Rhod 2-AM (5 μM with 0.05% Pluronic F127 
detergent) in Tyrode’s solution (containing in mM: 138 NaCl, 4 KCl, 2 CaCl2, 1 MgCl2, 0.33 NaH2PO4, 
and 10 HEPES) for 20 minutes at room temperature. Cells were then washed and maintained in Tyrode’s. 
A Leica SP2 microscope equipped with a 63×, oil immersion, N.A. 1.4 objective was used for confocal line 
scan imaging. The electronic zoom was adjusted to fit the cells, and the scan field was rotated to be along 
the long axis of  the cells. Static bright-field and fluorescence images were taken before measuring intracel-
lular Ca2+ release. Rhod-2-AM was excited at 543 nm and emission detected between 550 and 600 nm. 
Confocal line scan frequency was set at 400 Hz. Cardiomyocytes were paced for 10 seconds, during which 
line scan images of  normal Ca2+ transients were acquired. Following this, pacing was stopped and 10 mM 
caffeine solution was perfused into the dish. As soon as sarcoplasmic reticulum Ca2+ release was observed, 
perfusion was switched to normal Tyrode’s solution.
Cell culture. H9c2 cells were purchased from ATCC and cultured in DMEM with 10% FBS. Oxygen 
consumption rate (OCR) was measured with an XF24 Extracellular Flux Analyzer (Agilent Technologies, 
Seahorse Bioscience). H9c2 cells were seeded in an XF 24-well cell culture microplate at a density of  2,000 
cells/well. For Seahorse experiments, the following inhibitors were used: 1 μm oligomycin, 750 nM FCCP, 
1 μm rotenone, and 1 μm antimycin-A in the same injection port.
Histology. Freshly isolated ventricular tissue sections were loaded with dihydroethidium (150 μm) in 
serum-free media for 30 minutes at room temperature with shaking at 30 rpm, to visualized ROS. NADPH 
autofluorescence was acquired using a 2-photon laser at 720 nm excitation and emission at 380–550 nm. 
Images were acquired using a Zeiss 710 Microscope equipped with 10× objective and a Coherent Chame-
leon 2-photon laser (48).
NOX activity. NADPH-dependent superoxide production was measured in cellular homogenates using 
lucigenin-enhanced chemiluminescence as previously described (49). Cells were homogenized in Kreb’s 
buffer, pH 7.4 (130 mM NaCl, 5 mM KCl, 2 mM MgCl2, 1.5 mM CaCl2, 5 mM glucose, 35 mM phosphoric 
acid, and 20 mM HEPES). Homogenates were centrifuged at 1,000 g at 4°C for 10 minutes to remove the 
unbroken cells and debris. The pellet was resuspended in Kreb’s buffer containing 0.5 mM lucigenin fol-
lowed by the addition of  0.1 mM NADH as the substrate. Protein content was measured using the Bradford 
protein assay reagent. The samples were transferred to a 96-well plate at 50 μg of  protein per well. Photon 
emission in terms of  relative light units was measured in a Tecan 200 microplate reader after a 5-minute 
incubation in the dark. There was no measurable activity in the absence of  NADPH. Superoxide anion 
production was expressed as relative lucigenin luminescence. gp91ds-tat was purchased from Anaspec. 
Go6983 was purchased from Tocris.
RNA purification and gene expression analysis. Total RNA was purified from cells or hearts using TRIzol 
reagent according to the manufacturer’s instructions (Invitrogen). DNase-treated RNA was used for cDNA 
synthesis using the ProtoScript II First-Strand cDNA Synthesis Kit (New England Biolabs). Quantitative 
real-time PCR was performed with the SYBR Select Master Mix (Applied Biosystems). Incorporation of  
the SYBR green dye into the PCR products was monitored in real time with an Mx3000 sequence detection 
system (Stratagene). Samples were normalized against 18S ribosomal RNA. The sequences of  the primers 
have been described previously (11).
Protein purification and analysis. Isolated heart tissues or cells were homogenized in radioimmune pre-
cipitation assay buffer containing protease inhibitors (1 mM benzamidine, 1 mM phenylmethylsulfonyl 
fluoride, 10 μg/ml leupeptin, 10 μg/ml aprotinin, 5 mM ethylene glycol tetraacetic acid, and 2 mM eth-
ylene diamine tetraacetic acid; Sigma-Aldrich) as well as 1 mM dithiothreitol and phosphatase inhibitors 
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(Halt phosphatase inhibitor mixture, Thermo Fisher Scientific). Total protein extract was applied (25 μg) 
to SDS-PAGE and transferred onto nitrocellulose membranes. Antibodies were obtained from Millipore 
(PKCα, 05-154), Santa Cruz Biotechnology (β-actin, C4sc47778; JNK, D2sc7345; PKCβ, E3sc8049; PKCδ, 
C17sc213; and PKCε, E5sc1681), and Cell Signaling Technology (phospho-PKCδ, 9374S; phospho-JNK, 
2993S; phospho-JNK-Ser-63, 9261S; phospho-JNK-Ser-73, 9164S; and phospho-ERK, 9101).
Multiplex cytokine and phosphoprotein analysis. Cytokine concentrations in mouse serum were determined 
using the mouse cytokine/chemokine magnetic bead panel (Millipore) according to the manufacturer’s 
instructions. The final data were obtained and analyzed via the Bioplex Magpix multiplex reader system 
(Bio-Rad). Loading for the protein panels was normalized via determination of  total protein concentration 
(BCA Protein Assay kit, Pierce).
Measurement of  WBC count. We used ACK buffer-erythrocyte lysis buffer to isolate WBCs from total 
blood, incubated for 5–10 minutes on a rocker. This was followed by adding an equal volume of  cold phos-
phate-buffered saline (PBS), centrifuging at 300 g for 5 minutes at 2°C–8°C, and discarding the supernatant. 
The pellet was resuspended with ACK lysis buffer. We measured the WBCs using the TC20 Automated 
Cell Counter from Bio-Rad.
Statistics. Results are presented as the mean ± SEM. The unpaired t test was used for comparisons of  2 
means; a 2-tailed P value of  less than 0.05 was considered statistically significant. For groups of  2 or more 
ANOVA was used with post-hoc testing (Prism v5, GraphPad Software).
Study approval. Animal protocols were reviewed and approved by the Columbia University and Temple 
University Institutional Animal Care and Use Committees (New York, NY and Philadelphia, PA, respec-
tively) and were carried out in accordance with the NIH guidelines for the care and use of  laboratory animals.
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